Downloading...
Download

Acadia

ACAD Stock Soared to a Four-Month High. Acadia Pharmaceuticals shares are trading higher Wednesday after the company won summary judgement in a patent suit. Just then Acadia Surged upto 33% in regards to the news. Acadia Pharmaceuticals (ACAD) notched a win in a patent battle Wednesday pertaining to its Parkinson's drug, Nuplazid. ACAD stock soared to a four-month high. ACAD Stock: Cashing In On Nuplazid Nuplazid is an important drug for Acadia. It's currently approved to treat patients with psychosis due to Parkinson's disease. In the September quarter, Nuplazid brought in $144.8 million in sales, accounting for more than 68% of total sales. NASDAQ:ACAD is trading above the 50, 100, & 200-day moving average indicating a Bullish Bias.
NASDAQ:ACADLong
by DEXWireNews
ACAD (ACADIA PHARMACEUTICALS INC) BUY ACAD LONG SET UP, ACAD Gapped down over 25% to a New 52 week low. Price should bounce and fill in the Gap in the market ACAD also filled its previous Buy gap from Sep 4th 2019 Title: Buy ACAD (ACADIA Pharmaceuticals) Asset: Stock Platform: Robinhood/WeBull/Etrade/ 401k account Symbol: ACAD Type: Buy Market Execution / Buy Limit Time Frame: 1D Entry Price 1: $26.50 ACTIVE Entry Price 2: $22.50(PENDING) Stop Loss: $19.50 (70 Pips) Take Profit 1: $33.00 (70 pips) Take Profit 2: $38.00 (140 pips) Take Profit 3: $44.00 (200 pips) Take Profit 4: $54.00 (300pips) Status: 🏃🏽‍♂️Active🏃🏽‍♂️ Sector: Health Technology Industry: Biotechnology ACADIA Pharmaceuticals operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R Brann on July 16, 1993 and is headquartered in San Diego CA
NASDAQ:ACADLong
by MavRich_Trading
3
ACAD ACADIA PHARMACEUTICALS INC 5X GAINS COMING SOON (HODL)buy ACAD entry 1 $44.50 & entry 2 $42.50 sl $38.50 tp.1 $50.50 tp.2 $55.50 Tp.3 $60.00 Tp.4 $70.50 Tp.5 $80.00 many products releasing soon Sector: Health Technology Industry: Biotechnology Employees: 503 ACADIA Pharmaceuticals , Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. Valuation Market Capitalization 8.373B Enterprise Value ( MRQ ) 5.922B Enterprise Value/EBITDA ( TTM ) — Total Shares Outstanding ( MRQ ) 155.861M Number of Employees 503 Number of Shareholders 26 Price to Earnings Ratio ( TTM ) — Price to Revenue Ratio ( TTM ) 22.1988 Price to Book (FY) 11.6201 Price to Sales (FY) 22.7131 Balance Sheet Quick Ratio ( MRQ ) 7.1997 Current Ratio ( MRQ ) 7.2630 Debt to Equity Ratio ( MRQ ) 0.0141 Net Debt ( MRQ ) -642.407M Total Debt ( MRQ ) 8.999M Total Assets ( MRQ ) 747.45M Operating Metrics Return on Assets ( TTM ) -0.3812 Return on Equity ( TTM ) -0.4504 Return on Invested Capital ( TTM ) -0.4450 Revenue per Employee ( TTM ) 674107.3559 Price History Average Volume (10 day) 1.571M 1-Year Beta 0.7491 52 Week High 58.7200 52 Week Low 21.5600 Dividends Dividends Paid (FY) 0 Dividends Yield (FY) 0 Dividends per Share (FY) 0 Margins Net Margin ( TTM ) -0.6499 Gross Margin ( TTM ) 0.9621 Operating Margin ( TTM ) -0.6784 Pretax Margin ( TTM ) -0.6485 Income Statement Basic EPS (FY) -1.5982 Basic EPS ( TTM ) -1.5783 EPS Diluted (FY) -1.5982 Net Income (FY) -235.259M EBITDA ( TTM ) -245.781M Gross Profit ( MRQ ) 86.899M Gross Profit (FY) 327.732M Last Year Revenue (FY) 339.076M Total Revenue (FY) 339.076M Free Cash Flow ( TTM ) -135.258M
NASDAQ:ACADLong
by MavRich_Trading
2
ACAD ACADIA PHARMACEUTICALS INC 5X GAINS COMING SOON (HODL)many products releasing soon Sector: Health Technology Industry: Biotechnology Employees: 503 ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. Valuation Market Capitalization 8.373B Enterprise Value (MRQ) 5.922B Enterprise Value/EBITDA (TTM) — Total Shares Outstanding (MRQ) 155.861M Number of Employees 503 Number of Shareholders 26 Price to Earnings Ratio (TTM) — Price to Revenue Ratio (TTM) 22.1988 Price to Book (FY) 11.6201 Price to Sales (FY) 22.7131 Balance Sheet Quick Ratio (MRQ) 7.1997 Current Ratio (MRQ) 7.2630 Debt to Equity Ratio (MRQ) 0.0141 Net Debt (MRQ) -642.407M Total Debt (MRQ) 8.999M Total Assets (MRQ) 747.45M Operating Metrics Return on Assets (TTM) -0.3812 Return on Equity (TTM) -0.4504 Return on Invested Capital (TTM) -0.4450 Revenue per Employee (TTM) 674107.3559 Price History Average Volume (10 day) 1.571M 1-Year Beta 0.7491 52 Week High 58.7200 52 Week Low 21.5600 Dividends Dividends Paid (FY) 0 Dividends Yield (FY) 0 Dividends per Share (FY) 0 Margins Net Margin (TTM) -0.6499 Gross Margin (TTM) 0.9621 Operating Margin (TTM) -0.6784 Pretax Margin (TTM) -0.6485 Income Statement Basic EPS (FY) -1.5982 Basic EPS (TTM) -1.5783 EPS Diluted (FY) -1.5982 Net Income (FY) -235.259M EBITDA (TTM) -245.781M Gross Profit (MRQ) 86.899M Gross Profit (FY) 327.732M Last Year Revenue (FY) 339.076M Total Revenue (FY) 339.076M Free Cash Flow (TTM) -135.258M
NASDAQ:ACADLong
by MavRich_Trading
Acadia: Stochastic Oscillator UpturnStochastic Oscillator shows upturn for Acadia. Ichimoku Cloud support is very important in this case since today's session is not breaking it and could demonstrate positive trend force. Please note that biotech companies present high uncertainty. Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal. I am not a financial advisor
NASDAQ:ACADLong
by Investing_Fellow
Finding the upcoming support zone and the right time to sell/buyAcadia Pharmaceuticals has shown a downward swing during the past 2 business days or so. Before that it was on a very big run, which on my opinion was due to the high demand and the low buy/sell price. It will soon find support around the 32.67 up to the 38 zone (see the purple channel) based on the past downswing which i just stated. In the very near future it will also go on an run as big as the last one or maybe a little slower, but it will fall out again. In my opinion it would be better to buy soon, sell some when it breaks the channel and then sell more when it reaches the climax of the channel.
NASDAQ:ACAD
by AlbanSako